The Debt to Equity Ratio is a company’s total liabilities divided by its shareholder equity. It's the degree to which a company is financing its operations through debt v/s wholly owned funds

Lower than Industry Debt to Equity Ratio

Current ratio measures a company’s ability to pay short-term obligations. Higher is better

Higher than Industry Current Ratio

The EBITDA margin is the percent of revenue that the company retains after incurring all the direct and operational costs of the business

Higher than Industry EBITDA Margin

The net profit margin is net income or profit generated as a percentage of revenue and illustrates how much of each rupee in revenue translates to profit

Higher than Industry Net Profit Margin

Y-o-y growth in the total revenue represents increased potential for the company to increase their market share.Total revenue for the current quarter is compared with the same quarter of previous year to reduce the effects of seasonality

Increasing Total Revenue

Y-o-y growth in the net income represents increased profitability of the company.Net profit for the current quarter is compared with the same quarter of previous year to reduce the effects of seasonality

Decreasing Net Profit

Increasing EBITDA margin indicates increased profit efficiency without taking into account financial, accounting or tax implications

Constant EBITDA Margin

Increasing Net profit margins indicates the increasing profit to the shareholders with each unit of revenue

Constant Net Profit Margin

Y-o-y growth in the EBITDA represents how efficiently the company manages its expenses.EBITDA for the current quarter is compared with the same quarter of previous year to reduce the effects of seasonality

Decreasing EBIDTA

Gland Pharma Limited has informed the Exchange about Investor Presentation

Investor Presentation

Gland Pharma Limited has informed the Exchange about Investor Presentation on Q4FY22 Financial Results

Gland Pharma Limited has informed the Exchange about Investor Presentation on the Q1FY23 Financial Results

Gland Pharma Limited has informed the Exchange about Investor Presentation for Q2FY23

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Gland Pharma is engaged in manufacturing small volume parenterals (SVPs) and contract development services.

Gland Pharma Ltd

Gland Pharma Ltd

Scorecard

Financial Statements

What is an income statement?

Income Statement

Company Updates